Literature DB >> 18226773

Clinical implications of early mitral regurgitation in patients with reperfused acute myocardial infarction.

Nazario Carrabba1, Guido Parodi, Renato Valenti, Merita Shehu, Angela Migliorini, Gentian Memisha, Giovanni M Santoro, David Antoniucci.   

Abstract

BACKGROUND: The mechanisms by which mitral regurgitation (MR) may lead to an adverse prognosis after reperfused acute myocardial infarction (AMI) have not been fully investigated. We hypothesized that in the early phase of ST-elevation AMI, MR may lead to progressive left ventricular (LV) remodeling and subsequent heart failure. METHODS AND
RESULTS: A series of 184 patients with AMI successfully treated with primary angioplasty underwent serial two-dimensional echocardiography at admission, at 1 and 6 months, and at 6-month angiography. The mean follow-up was 18 +/- 7 months. On the basis of color Doppler, MR was graded from 0 (none) to 4 (severe). Patients were divided into group 1 (n = 146) with an MR grade of < or = 1 and group 2 (n = 38) with an MR grade of > or = 2. The regurgitant volume and effective regurgitant orifice area of MR were significantly higher in group 2 than in group 1 (36.7 +/- 12.9 mL/beat vs 4.67 +/- 3.2 mL/beat, P < .0001; 22.5 +/- 7.6 mm(2) vs 5.8 +/- 5.7 mm(2), P < .0001, respectively). LV end-diastolic volume progressively increased in group 2 and was significantly higher than in group 1 at 6 months (113.8 +/- 31.8 mL vs 96.9 +/- 34.1 mL, P = .0002), with a higher prevalence of LV remodeling (66% vs 22%, P < .0001). At 2 years, the incidence of heart failure was higher in group 2 than in group 1 (39% vs 12%, P < .0002). A significant correlation was found between effective regurgitant orifice area of MR and baseline to 6-month change of LV end-diastolic volume (P = .001). By stepwise multivariate regression analysis effective regurgitant orifice area of early MR was an independent predictor of LV remodeling (P = .001) and late heart failure (hazard ratio: 1.069, 95% confidence interval 1.033-1.106, P < .0001, Cox analysis).
CONCLUSION: In reperfused AMI, early high-degree MR is an important predictor of both LV dilation and subsequent heart failure.

Entities:  

Mesh:

Year:  2008        PMID: 18226773     DOI: 10.1016/j.cardfail.2007.08.005

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  5 in total

1.  A Novel Method in the Stratification of Post-Myocardial-Infarction Patients Based on Pathophysiology.

Authors:  Ben He; Heng Ge; Fan Yang; Yujun Sun; Zheng Li; Meng Jiang; Yiting Fan; Jun Pu; Xuedong Shen
Journal:  PLoS One       Date:  2015-06-19       Impact factor: 3.240

2.  Frequency of ischemic mitral regurgitation after first-time acute myocardial infarction and its relation to infarct location and in-hospital mortality.

Authors:  Afsoon Fazlinezhad; Mitra Dorri; Ali Azari; Leila Bigdelu
Journal:  J Tehran Heart Cent       Date:  2014-07-06

3.  Outcomes of ischaemic mitral regurgitation in anterior versus inferior ST elevation myocardial infarction.

Authors:  Amgad Mentias; Mohammad Q Raza; Amr F Barakat; Elizabeth Hill; Dalia Youssef; Amar Krishnaswamy; Milind Y Desai; Brian Griffin; Stephen Ellis; Venu Menon; E Murat Tuzcu; Samir R Kapadia
Journal:  Open Heart       Date:  2016-11-10

4.  Predictors of left ventricular remodeling after ST-elevation myocardial infarction.

Authors:  Tom Hendriks; Minke H T Hartman; Pieter J J Vlaar; Niek H J Prakken; Yldau M Y van der Ende; Chris P H Lexis; Dirk J van Veldhuisen; Iwan C C van der Horst; Erik Lipsic; Robin Nijveldt; Pim van der Harst
Journal:  Int J Cardiovasc Imaging       Date:  2017-04-07       Impact factor: 2.357

5.  Sirtuin3 protects aged human mesenchymal stem cells against oxidative stress and enhances efficacy of cell therapy for ischaemic heart diseases.

Authors:  Dong-Yang Zhang; Chun-Feng Zhang; Bi-Cheng Fu; Lu Sun; Xue-Qing Wang; Wei Chen; Wei Liu; Kai-Yu Liu; Guo-Qing Du; Chong-Yi Ma; Shu-Lin Jiang; Ren-Ke Li; Hai Tian
Journal:  J Cell Mol Med       Date:  2018-08-09       Impact factor: 5.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.